@hubboot01
Active 3 hours, 49 minutes ago
The other parameters-sex, mutational status, association of immunotherapy (PD-1i and CTLA-4i) and overall response-were not significantly associated with late-onset irAEs. In our real-life data study, the median onset time of grade III-IV irAES was 128 days after the initiation of immune checkpoint inhibitors (ICI) therapy. Conclusions Our […] View